was read the article
array:21 [ "pii" => "S217357432100157X" "issn" => "21735743" "doi" => "10.1016/j.reumae.2019.12.005" "estado" => "S300" "fechaPublicacion" => "2021-10-01" "aid" => "1402" "copyrightAnyo" => "2020" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Reumatol Clin. 2021;17:490" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemAnterior" => array:19 [ "pii" => "S2173574320301404" "issn" => "21735743" "doi" => "10.1016/j.reumae.2020.02.005" "estado" => "S300" "fechaPublicacion" => "2021-10-01" "aid" => "1404" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Reumatol Clin. 2021;17:489-90" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Atypical familial Mediterranean fever with PFAPA-Like symptoms and psoriasis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "489" "paginaFinal" => "490" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Variante atípica PFAPA-<span class="elsevierStyleItalic">like</span> de la fiebre mediterránea familiar asociada a psoriasis" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Felipe Blasco, Ángel García A, María Dolores Martos, Sandra Muñoz" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Felipe" "apellidos" => "Blasco" ] 1 => array:2 [ "nombre" => "Ángel" "apellidos" => "García A" ] 2 => array:2 [ "nombre" => "María Dolores" "apellidos" => "Martos" ] 3 => array:2 [ "nombre" => "Sandra" "apellidos" => "Muñoz" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X20300280" "doi" => "10.1016/j.reuma.2020.02.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X20300280?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574320301404?idApp=UINPBA00004M" "url" => "/21735743/0000001700000008/v1_202110061021/S2173574320301404/v1_202110061021/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Systemic sclerosis related interstitial lung disease: What is the recommended treatment?" "tieneTextoCompleto" => true "saludo" => "<span class="elsevierStyleItalic">Sr. Editor</span>:" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "490" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Metin Işık, Murat Kara" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Metin" "apellidos" => "Işık" "email" => array:1 [ 0 => "metin1721978@yahoo.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Murat" "apellidos" => "Kara" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Internal Medicine and Rheumatology, Özel 100. Yıl Hospital, Çukurambar, Muhsin Yazıcıoğlu Caddesi No: 54, Çankaya, Ankara, Turkey" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Physical Medicine and Rehabilitation, Hacettepe University Hospital, Sıhhiye, Ankara, Turkey" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Enfermedad pulmonar intersticial relacionada con la esclerosis sistémica: ¿cuál es el tratamiento recomendado?" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">We have read the article by Sobolewski et al.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">1</span></a> with great interest and we sincerely congratulate them for highlighting the current developments in the management of systemic sclerosis (SSc). Although they wanted to gather the newest data about the aetiology, pathophysiology and management, the part regarding the management of SSc related interstitial lung disease (SSc-ILD) has some clerical error. Firstly, they specified that patients with SSc-ILD have stable or slowly progressive disease and only 25–30% of them need immunosuppressive treatment. This statement creates an impression that ILD in SSc is not a serious complication. However, in the previous part of the same manuscript, it is stated that SSc-ILD is one of the major causes of morbidity and mortality and we know that SSc-ILD is not a benign complication of the disease. Secondly, they reported that mycophenolate mofetil (MMF) is the preferred first line agent for the treatment of SSc-ILD. On the other hand, in the following paragraph, it is written that intravenous cyclophosphamide (CYC) is the recommended first line therapy for SSc-ILD and MMF is a good alternative treatment. In this regard, European League Against Rheumatism (EULAR) also recommends CYC for SSc-ILD in the first line, but not MMF.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">In conclusion, as complications in SSc is still characterized by a severe course and high risk of early death, the importance and severity of ILD in SSc patients should be highlighted and the recommended first line treatment for SSc-ILD should be clarified.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:2 [ 0 => array:3 [ "identificador" => "bib0015" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systemic sclerosis – multidisciplinary disease: clinical features and treatment" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Sobolewski" 1 => "M. Maślińska" 2 => "M. Wieczorek" 3 => "Z. Łagun" 4 => "A. Malewska" 5 => "M. Roszkiewicz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.5114/reum.2019.87619" "Revista" => array:6 [ "tituloSerie" => "Reumatologia" "fecha" => "2019" "volumen" => "57" "paginaInicial" => "221" "paginaFinal" => "233" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31548749" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0020" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Update of EULAR recommendations for the treatment of systemic sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "O. Kowal-Bielecka" 1 => "J. Fransen" 2 => "J. Avouac" 3 => "M. Becker" 4 => "A. Kulak" 5 => "Y. Allanore" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/annrheumdis-2016-209909" "Revista" => array:6 [ "tituloSerie" => "Ann Rheum Dis" "fecha" => "2017" "volumen" => "76" "paginaInicial" => "1327" "paginaFinal" => "1339" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27941129" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735743/0000001700000008/v1_202110061021/S217357432100157X/v1_202110061021/en/main.assets" "Apartado" => array:4 [ "identificador" => "8400" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735743/0000001700000008/v1_202110061021/S217357432100157X/v1_202110061021/en/main.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217357432100157X?idApp=UINPBA00004M" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 5 | 8 | 13 |
2024 October | 28 | 31 | 59 |
2024 September | 28 | 13 | 41 |
2024 August | 41 | 25 | 66 |
2024 July | 34 | 23 | 57 |
2024 June | 36 | 29 | 65 |
2024 May | 35 | 23 | 58 |
2024 April | 25 | 18 | 43 |
2024 March | 26 | 25 | 51 |
2024 February | 23 | 27 | 50 |
2024 January | 22 | 21 | 43 |
2023 December | 32 | 18 | 50 |
2023 November | 33 | 27 | 60 |
2023 October | 25 | 25 | 50 |
2023 September | 38 | 32 | 70 |
2023 August | 28 | 12 | 40 |
2023 July | 21 | 22 | 43 |
2023 June | 30 | 29 | 59 |
2023 May | 61 | 24 | 85 |
2023 April | 15 | 10 | 25 |
2023 March | 34 | 20 | 54 |
2023 February | 21 | 23 | 44 |
2023 January | 10 | 18 | 28 |
2022 December | 33 | 26 | 59 |
2022 November | 27 | 16 | 43 |
2022 October | 30 | 25 | 55 |
2022 September | 27 | 28 | 55 |
2022 August | 25 | 38 | 63 |
2022 July | 32 | 40 | 72 |
2022 June | 31 | 28 | 59 |
2022 May | 25 | 20 | 45 |
2022 April | 31 | 44 | 75 |
2022 March | 1 | 2 | 3 |